While I agree that the comment you replied to seems a bit over the top, I don’t think the answer to your question is as obvious as you make it out to be.

1. If the AI is more effective at finding successful cancer treatment for Little Endians versus Big Endians, then there is a non-zero chance that the AI will be deemed discriminatory. This could play out in a number of ways, but restricted access is certainly one of them. I live in California, and I also think that there is a non-zero chance of this happening here. It all depends on how the treatment and data are presented.

2. If the manufacturer of said treatment is anti-union, will the treatment options be distributable in certain parts of Europe?